Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HIV-1 envelope glycoprotein gp120 third variable (V3) loop is a critical 35-amino-acid region of the viral surface protein that facilitates entry into host cells [1]. It is primarily responsible for determining viral tropism, as it interacts directly with the host cell co-receptors CCR5 or CXCR4 after the initial binding of gp120 to the CD4 receptor [2]. This interaction triggers the necessary conformational changes in the gp41 subunit to initiate viral-cell membrane fusion [3]. Due to its high accessibility and functional importance, the V3 loop is a major target for neutralizing antibodies and is often referred to as the principal neutralizing determinant (PND) [4]. However, the loop is characterized by extreme sequence variability, which allows the virus to evade host immune responses and develop resistance to entry inhibitors [5]. Therapeutic strategies targeting this region include broadly neutralizing antibodies (bNAbs) like 10-1074 and small molecule inhibitors that interfere with the co-receptor binding interface [1][6]. [1] Huang, C. C., et al. (2005). "Structure of a V3-containing HIV-1 gp120 core." Science. [2] Wilen, C. B., et al. (2012). "HIV-1 Entry and Membrane Fusion." Cold Spring Harbor Perspectives in Medicine. [3] NIH/NIAID. (2023). "HIV Structure and Life Cycle." [4] Zolla-Pazner, S. (2004). "Focusing on the V3 loop for HIV vaccine design." Nature Reviews Immunology. [5] Fouchier, R. A., et al. (1992). "Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule." Journal of Virology. [6] Caskey, M., et al. (2017). "Antibody 10-1074 suppresses viremia in HIV-1-infected individuals." Nature Medicine.
Entry inhibition by blocking the interaction between the V3 loop and host cell co-receptors (CCR5 or CXCR4) or neutralizing the virus by binding directly to the V3 loop glycans and peptide backbone.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIV-1 envelope glycoprotein gp120 third variable loop (gp120 V3 loop).